Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bactiguard Holding ABCHIX:BACTBS 52 EBITDA Margin % is 6.24% as of Jun. 2026, which is 46% below its 10-year median of 11.64. GuruFocus rates CHIX:BACTBS with a GF Score™ of 52/100 and a GF Value™ of kr242.71. The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Bactiguard Holding AB ranks better than 83.58% on this metric.
Bactiguard Holding AB (CHIX:BACTBs) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bactiguard Holding AB EBITDA Margin % Related Terms
Bactiguard Holding AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bactiguard Holding AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BACTBS vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Bactiguard Holding AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bactiguard Holding AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bactiguard Holding AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bactiguard Holding AB (CHIX:BACTBS) has a EBITDA Margin % of 6.24% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bactiguard Holding AB and its competitors. This is 46% below median its historical median of 11.64. According to the industry distribution chart, Bactiguard Holding AB ranks #134 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 16.4%.
Is Bactiguard Holding AB's EBITDA Margin % too high?
Bactiguard Holding AB's current EBITDA Margin % of 6.24% is 46% below median its 10-year median of 11.64. The Medical Devices & Instruments industry median EBITDA Margin % is 7.59. Bactiguard Holding AB's value of 6.24% is 17.8% below this industry median. Based on the distribution chart, Bactiguard Holding AB ranks #134 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bactiguard Holding AB has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bactiguard Holding AB ranks #134 out of 816 companies for EBITDA Margin %. This places Bactiguard Holding AB in the top 16% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.59. Bactiguard Holding AB's value of 6.24% is 17.8% below this benchmark. While the company's 10-year median is 11.64 vs. the industry median of 7.59, Bactiguard Holding AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.59, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bactiguard Holding AB's current EBITDA Margin % of 6.24% is 17.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bactiguard Holding AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bactiguard Holding AB's current EBITDA Margin % is 6.24%, which is 46% below median its own 10-year median of 11.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current EBITDA Margin % of 6.24%. The stock's GF Value™ is kr242.71, compared to a current price of kr128.60 — trading 47% below its estimated fair value. The current EBITDA Margin % is 6.24%, which is 46% below median its 10-year median of 11.64 and 17.8% below the Medical Devices & Instruments industry median of 7.59. Bactiguard Holding AB's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current EBITDA Margin % is 6.24% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of kr128.60 is trading 47% below its estimated GF Value™ of kr242.71.
Key valuation signals for CHIX:BACTBS:
EBITDA Margin %: 6.24% (46% below median its 10-year median of 11.64)
GF Value™: kr242.71 vs. price of kr128.60 (47% below fair value)
Industry Position: 17.8% below the Medical Devices & Instruments median (#134 of 816)
No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
52GF Score
Get the complete analysis for CHIX:BACTBS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BACTBS has been successfully added to your 
